Naturally occurring dominant resistance mutations to hepatitis c virus protease and polymerase inhibitors in treatment-naive patients
Thomas Kuntzen,Joerg Timm,Andrew Berical,Niall Lennon,Aaron M. Berlin,Sarah Young,Bongshin Lee,David Heckerman,Jonathan M. Carlson,Laura L. Reyor,Marianna Kleyman,Cory M. McMahon,Christopher E. Birch,Julian Schulze zur Wiesch,Timothy Ledlie,Michael Koehrsen,Chinnappa D. Kodira,Andrew Roberts,Georg M. Lauer,Hugo R. Rosen,Florian Bihl,Andreas Cerny,Ulrich Spengler,Zhimin Liu,Arthur Y. Kim,Yanming Xing,Arne Schneidewind,Margaret A. Madey,Jaquelyn Fleckenstein,Vicki M. Park,James E. Galagan,Chad Nusbaum,Bruce D. Walker,Bruce D. Walker,Gerond Lake-Bakaar,Eric S. Daar,Ira M. Jacobson,Edward D. Gomperts,Brian R. Edlin,Sharyne M. Donfield,Raymond T. Chung,Andrew H. Talal,Tony N. Marion,Bruce W. Birren,Matthew R. Henn,Todd M. Allen +45 more
TLDR
Naturally occurring dominant STAT‐C resistance mutations are common in treatment‐naïve patients infected with HCV genotype 1, and their influence on treatment outcome should be characterized to evaluate possible benefits of drug resistance testing for individual tailoring of drug combinations when treatment options are limited due to previous nonresponse to peginterferon and ribavirin.About:
This article is published in Hepatology.The article was published on 2008-12-01 and is currently open access. It has received 355 citations till now. The article focuses on the topics: Ribavirin & Drug resistance.read more
Citations
More filters
Journal ArticleDOI
Viral Quasispecies Evolution
TL;DR: The understanding of viruses as quasispecies has led to new antiviral designs, such as lethal mutagenesis, whose aim is to drive viruses toward low fitness values with limited chances of fitness recovery.
Nucleotide Polymerase Inhibitor So fos bu vir plus Ribavirin for Hepatitis C
E.J. Gane,Catherine A.M. Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,William T. Symonds,R. Hindes,M.M. Berrey +7 more
TL;DR: Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection, and the rate of sustained virologic response 24 weeks after therapy is reported.
Journal ArticleDOI
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward Gane,Catherine A.M. Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,William T. Symonds,R. Hindes,M.M. Berrey +7 more
TL;DR: In this paper, the authors evaluated sofosbuvir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interfon-free regimens for the treatment of hepatitis C virus (HCV) infection.
Journal ArticleDOI
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin,Stefan Zeuzem +1 more
TL;DR: The parameters that determine resistance, genotypic and phenotypic resistance profiles of DAA agents, and strategies to avoid the selection of resistant variants are reviewed.
Journal ArticleDOI
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
TL;DR: Geno- and phenotypic resistance testing as well as clinical data on the importance of RAVs for conventional triple therapies with sofosbuvir, simeprevir, and daclatasvir and available interferon-free DAA combinations are discussed.
References
More filters
Journal ArticleDOI
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools.
TL;DR: ClUSTAL X is a new windows interface for the widely-used progressive multiple sequence alignment program CLUSTAL W, providing an integrated system for performing multiple sequence and profile alignments and analysing the results.
Journal ArticleDOI
Hepatitis C Virus Infection
Georg M. Lauer,Bruce D. Walker +1 more
TL;DR: The institution of blood-screening measures in developed countries has decreased the risk of transfusion-associated hepatitis to a negligible level, but new cases continue to occur mainly as a result of injection-drug use and, to a lesser degree, through other means of percutaneous or mucous-membrane exposure.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Christoph Sarrazin,Tara L. Kieffer,Doug J. Bartels,Brian L. Hanzelka,Ute Müh,Martin W. Welker,Dennis Wincheringer,Yi Zhou,Hui–May Chu,Chao Lin,Christine J. Weegink,Henk W. Reesink,Stefan Zeuzem,Ann D. Kwong +13 more
TL;DR: Resistant HCV isolates are selected rapidly during therapy with the highly active protease inhibitor telaprevir, and changes in the frequency of mutations after the end of dosing showed an inverse relationship between in vivo viral fitness and resistance.
Journal ArticleDOI
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Martin S. Hirsch,Françoise Brun-Vézinet,Bonaventura Clotet,Brian Conway,Daniel R. Kuritzkes,Richard T. D'Aquila,Lisa M. Demeter,Scott M. Hammer,Victoria A. Johnson,Clive Loveday,John W. Mellors,Donna M. Jacobsen,Douglas D. Richman +12 more
TL;DR: The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV- 1 resistance testing.
Related Papers (5)
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode,Nicole Forestier,Geoffrey Dusheiko,Peter Ferenci,Stanislas Pol,Tobias Goeser,Jean-Pierre Bronowicki,Marc Bourlière,Shahin Gharakhanian,Leif Bengtsson,Lindsay McNair,Shelley George,Tara L. Kieffer,Ann D. Kwong,Robert S. Kauffman,John Alam,Jean-Michel Pawlotsky,Stefan Zeuzem +17 more